These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 18083272

  • 1. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
    Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C.
    J Am Acad Dermatol; 2008 Feb; 58(2):224-31. PubMed ID: 18083272
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, Antoniou C, Ioannides D.
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 5. Approach to managing patients with nail psoriasis.
    Reich K.
    J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators.
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [Abstract] [Full Text] [Related]

  • 11. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
    Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Molta CT, Boggs R.
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Eur J Dermatol; 2007 Aug; 17(5):381-6. PubMed ID: 17673380
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
    Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P.
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950
    [Abstract] [Full Text] [Related]

  • 16. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M, Bonesrønning JH.
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [Abstract] [Full Text] [Related]

  • 17. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
    Rigopoulos D, Gregoriou S, Daniel Iii CR, Belyayeva H, Larios G, Verra P, Stamou C, Kontochristopoulos G, Avgerinou G, Katsambas A.
    Dermatology; 2009 Mar; 218(4):338-41. PubMed ID: 19212110
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators.
    Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
    [Abstract] [Full Text] [Related]

  • 20. Treatment of severe psoriasis with infliximab: report of two cases.
    Peternel S, Prpić-Massari L, Guina T, Novak S, Brajac I, Kastelan M.
    Acta Dermatovenerol Croat; 2009 Feb; 17(3):204-6. PubMed ID: 19818221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.